SISTEMA INSULINOPODOBNYKh FAKTOROV ROSTA PRI NOVOOBRAZOVANIYaKh YaIChNIKOV
- Authors: Isaeva ER1, Kushlinskiy DN1, Mishkov SV1
-
Affiliations:
- Issue: Vol 16, No 4 (2016)
- Pages: 104-105
- Section: Articles
- URL: https://journals.eco-vector.com/MAJ/article/view/9623
- DOI: https://doi.org/10.17816/MAJ164104-105
- ID: 9623
Cite item
Abstract
Full Text
References
- IGF-I in epithelial ovarian cancer and its role in disease progression / Brokaw J., Katsaros D., Wiley A., Lu L., Su D., Sochirca O., de la Longrais I. A., Mayne S., Risch H., Yu H. // Growth Factors.- 2007.- Vol. 25, № 5.- P. 346-354.
- Huang G. S., Brouwer-Visser J., Ramirez M. J. et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer // Clin. Cancer Res.- 2010. -Vol. 16, № 11.- P. 2999-3010.
- Bruchim I., Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies // Expert. Opin. Ther. Targets.- 2013.- Vol. 17, № 3.- P. 307-320.
- High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer / Sayer R. A., Lancaster J. M., Pittman J., Gray J., Whitaker R., Marks J. R., Berchuck A. // Gynecol. Oncol.- 2005.- Vol. 96, № 2.- P. 355-361.
- IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer / Spentzos D., Cannistra S. A., Grall F., Levine D. A., Pillay K., Libermann T. A., Mantzoros C. S. // Endocr. Relat. Cancer.- 2007.- Vol. 14, № 3.- P. 781-790.